.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Covington
Baxter
Teva
Harvard Business School
US Army
Express Scripts
Colorcon
Merck
Chubb

Generated: November 19, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021859

« Back to Dashboard
NDA 021859 describes HYLENEX RECOMBINANT, which is a drug marketed by Halozyme Therap and is included in one NDA. It is available from two suppliers. There is one patent protecting this drug. Additional details are available on the HYLENEX RECOMBINANT profile page.

The generic ingredient in HYLENEX RECOMBINANT is hyaluronidase recombinant human. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the hyaluronidase recombinant human profile page.

Summary for 021859

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Formulation / Manufacturing:see details

Pharmacology for NDA: 021859

Ingredient-typeGlycoside Hydrolases

Suppliers and Packaging for NDA: 021859

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
HYLENEX RECOMBINANT
hyaluronidase recombinant human
INJECTABLE;INJECTION 021859 NDA Halozyme, Inc. 18657-117 18657-117-04 4 BOX in 1 CARTON (18657-117-04) > 1 VIAL in 1 BOX (18657-117-02) > 1 mL in 1 VIAL (18657-117-01)
HYLENEX RECOMBINANT
hyaluronidase recombinant human
INJECTABLE;INJECTION 021859 NDA Baxter Healthcare Corporation 60977-319 60977-319-03 4 BOX in 1 CARTON (60977-319-03) > 1 VIAL, SINGLE-DOSE in 1 BOX (60977-319-02) > 1 mL in 1 VIAL, SINGLE-DOSE (60977-319-44)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength150 UNITS/ML
Approval Date:Dec 2, 2005TE:RLD:Yes
Patent:► SubscribePatent Expiration:Sep 23, 2027Product Flag?YSubstance Flag?YDelist Request?


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Daiichi Sankyo
US Army
Queensland Health
Fuji
Johnson and Johnson
Teva
Novartis
McKinsey
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot